抗精神病药市场:现状分析·预测 (2021年～2027年)

全球抗精神病药的市场规模在预测期间内预计将以预计将记录7.3％大幅度的年复合成长率。

社会老龄化、精神分裂症和双相情感障碍等精神疾病人口的增加以及消费者对精神健康的认识等因素正在显着增长。

本报告提供全球抗精神病药的市场调查，彙整市场定义和概要，市场成长的各种影响因素分析，市场规模的转变·预测，各种区分·地区/各主要国家的明细，法律制度，供需趋势，竞争环境，主要企业简介等资讯。

目录

第1章 简介

第2章 调查手法·前提条件

第3章 市场概要

第4章 摘要整理

第5章 抗精神病药市场:COVID-19影响

第6章 抗精神病药市场:收益的转变·预测

第7章 市场洞察:各治疗层级

• 第一代
• 第2代
• 第3代

第8章 市场洞察:各用途

• 思觉失调症
• 失智症
• 躁郁症
• 打
• 其他

第9章 市场洞察:各流通管道

• 医院药局
• 零售药局
• 线上药局
• 其他

第10章 市场洞察:各地区

• 北美
• 欧洲
• 亚太地区
• 其他地区

第11章 抗精神病药市场:市场动态

• 推动市场要素
• 市场课题
• 影响分析

第12章 抗精神病药市场:市场机会

第13章 抗精神病药市场:趋势

第14章 政策·相关法规

第15章 需求方面·供给面的分析

• 需求面分析
• 供给面分析

第16章 价值链分析

第17章 竞争模式

• 竞争情形

第18章 企业简介

• Eli Lily and Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Johnson & Johnson
• Otsuka Pharmaceutical Co, Ltd.
• Pfizer Inc.
• AbbVie Inc.
• Bristol-Myers Squibb
• Teva Pharmaceuticals
• Dr. Reddy's Laboratories

第19章 免责声明

The global antipsychotic drugs market is experiencing significant growth due to the increasing aging population, mental health disorders such as schizophrenia and bipolar disorder amongst the population, and awareness regarding the mental health among consumers. In March 2020 Dr. Reddy's Laboratories announced the launch of Ziprasidone Mesylate for injection, 20 mg (base)/ml single-dose vials, which is the generic therapeutic equivalent of Pfizer's Geodon injection, in the United States. The ziprasidone injection is used to treat occurrences of severe agitation in patients with schizophrenia. Thus, it works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain. Furthermore, ziprasidone injection is used when quick relief of your symptoms is required. Therefore, the market for antipsychotic drugs is expected to witness a significant CAGR of 7.3% during the forecast period.

Global antipsychotic drugs market is expected to register a significant CAGR of around 6% over the period of 2021-2027. This is mainly due to the high prevalence of neurological disorders and stringent government regulations coupled with the growing focus of major stakeholders in the healthcare system to adopt to make antipsychotic drug products more sustainable with fewer side effects and eco-friendlier. Major healthcare companies are investing heavily in their products due to rising infertility cases, an increase in the demand for at-home diagnostic devices, awareness of healthcare expenditure, and the rising incidence of gynecological disorders. For instance, according to the World Health Organization (WHO), in 2018, globally more than 300 million individuals suffered from depression. The considerably large number of people suffering from mental stress increases the demand for antipsychotic drugs. As a result, the government is focusing on raising awareness about the illnesses and the effect which significantly contributes to the market for antipsychotic drugs. Therefore, the market for antipsychotic drugs is expected to witness significant growth during the forecast period

Eli Lily and Company, AstraZeneca plc, GlaxoSmithKline plc, Johnson & Johnson, Otsuka Pharmaceutical Co, Ltd., Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb, Teva Pharmaceuticals, Dr. Reddy's Laboratories are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst Therapeutic class, second generation category accounted for the majority share in the market in 2020"

Based on therapeutic class, the market is classified into first generation, second generation, and third generation. Amongst types, the second-generation category accounted for a significant share of the market. This is mainly due to this segment dominance is attributable to the presence of a large number of second-generation antipsychotic drugs in the global markets. Over the forthcoming years, the rising popularity of mental health disorders among the younger generation is likely to boost the demand for antipsychotic drugs.

"Amongst Application, schizophrenia is expected to witness highest CAGR during the forecast period"

Based on product, the market is categorized into schizophrenia, dementia, bipolar disorder, depression, and others. Among these, schizophrenia is expected to witness the highest CAGR during the forecast period. Schizophrenia is affecting a large number of people and is expected to support the growth of the segment over the forecast period. For instance, as per WHO, Schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide. This rate is 1 in 222 people (0.45%) among adults. These results in serious mental illnesses that affect how a person thinks, feels, and behaves. The continuous development of the new products and procedures is likely to strengthen the market of the segment during the forecast period

"North America to witness significant growth during the forecast period"

North America is expected to show significant growth in the antipsychotic drugs market. The major contributors to the growth of this market are US and Canada. The increase in technology development in emerging economies, as well as the expansion of the healthcare industry, has contributed to the growth of the North America market. North America has a higher adoption rate of technologically advanced and innovative solutions and drugs. The enhanced mental awareness regarding the availability of various antipsychotic drugs has propelled the growth of the market in the region. Furthermore, increasing geriatric population and new product launches, and various developmental strategies adopted by the regional market will drive market growth. The endorsement of increasing demand for mental health awareness campaigns also significantly contributed to the considerable growth of the state. As per the national alliance on mental illness, about 1 in 5 U.S. adults experience mental illness each year.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

Global antipsychotic drugs market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Limitation
• 1.3. Stakeholders
• 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Antipsychotic Drugs Market
• 2.2. Research Methodology of the Antipsychotic Drugs Market
• 2.3. Forecasting Method
• 2.4. Respondent Profile
• 2.5. Main Objective of the Antipsychotic Drugs Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL ANTIPSYCHOTIC DRUGS MARKET COVID-19 IMPACT

6 GLOBAL ANTIPSYCHOTIC DRUGS MARKET REVENUE (USD BN), 2019-2027F

7 MARKET INSIGHTS BY THERAPEUTIC CLASS

• 7.1. First Generation
• 7.2. Second Generation
• 7.3. Third Generation

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Schizophrenia
• 8.2. Dementia
• 8.3. Bipolar Disorder
• 8.4. Depression
• 8.5. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Hospital Pharmacies
• 9.2. Retail Pharmacies
• 9.3. Online Pharmacies
• 9.4. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. UK
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Australia
  • 10.3.5. Rest of Asia-Pacific
• 10.4. Rest of World

11 ANTIPSYCHOTIC DRUGS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 ANTIPSYCHOTIC DRUGS MARKET OPPORTUNITIES

13 ANTIPSYCHOTIC DRUGS MARKET TRENDS

14 POLICY & REGULATORY FRAMEWORK

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porter's Five Forces Analysis

18 COMPANY PROFILED

• 18.1. Eli Lily and Company
• 18.2. AstraZeneca plc
• 18.3. GlaxoSmithKline plc
• 18.4. Johnson & Johnson
• 18.5. Otsuka Pharmaceutical Co, Ltd.
• 18.6. Pfizer Inc.
• 18.7. AbbVie Inc.
• 18.8. Bristol-Myers Squibb
• 18.9. Teva Pharmaceuticals
• 18.10. Dr. Reddy's Laboratories

19 DISCLAIMER